Evaluating the evidence behind the surrogate measures included in the FDA's table of surrogate endpoints as supporting approval of cancer drugs
Authors:
Open Access
- 1 April 2020
- journal article
- research article
- Published by Elsevier in eClinicalMedicine
- Vol. 21, 100332
Abstract
No abstract availableKeywords
Funding Information
- Harvard-MIT Center for Regulatory Science
- U.S. Food and Drug Administration
- Arnold Ventures
This publication has 28 references indexed in Scilit:
- Progression-free survival as surrogate end point for overall survival in clinical trials of HER2-targeted agents in HER2-positive metastatic breast cancerAnnals of Oncology, 2016
- Correlation between progression-free survival and overall survival in metastatic breast cancer patients receiving anthracyclines, taxanes, or targeted therapies: a trial-level meta-analysisBreast Cancer Research and Treatment, 2015
- Pathologic Complete Response As a Potential Surrogate for the Clinical Outcome in Patients With Breast Cancer After Neoadjuvant Therapy: A Meta-Regression of 29 Randomized Prospective StudiesJournal of Clinical Oncology, 2014
- Everolimus plus exemestane for hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: overall survival results from BOLERO-2Annals of Oncology, 2014
- Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysisThe Lancet, 2014
- New FDA Breakthrough-Drug Category — Implications for PatientsNew England Journal of Medicine, 2014
- Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast CancerNew England Journal of Medicine, 2012
- Progression-free survival as a surrogate endpoint in advanced breast cancerInternational Journal of Technology Assessment in Health Care, 2008
- Evaluation of Tumor Response, Disease Control, Progression-Free Survival, and Time to Progression As Potential Surrogate End Points in Metastatic Breast CancerJournal of Clinical Oncology, 2008
- Correlation of changes between 2-year disease-free survival and 5-year overall survival in adjuvant breast cancer trials from 1966 to 2006Annals of Oncology, 2007